Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite the availability of a vaccine for over 80 years, the tuberculosis epidemic continues to be a major cause of mortality and morbidity throughout the world. The factors contributing to the resurgence of tuberculosis and the possible explanations for the failure of the current vaccine, bacille Calmette-Guérin, are discussed. The nature of protective immunity to Mycobacterium tuberculosis and how this relates to the development of new candidate vaccines is then considered. The issues surrounding the progression of the most promising candidates into Phase I clinical trials are also discussed.

Original publication

DOI

10.1586/14760584.3.3.299

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

06/2004

Volume

3

Pages

299 - 306

Keywords

Animals, Antigens, Bacterial, Clinical Trials, Phase I as Topic, Disease Models, Animal, Humans, Mycobacterium tuberculosis, Tuberculosis Vaccines, Tuberculosis, Pulmonary, Vaccines, DNA